Alpha Tau Medical shares surge 50.59% after-hours after first patient treated in Alpha DaRT glioblastoma pilot study.

Alpha Tau Medical Ltd. surged 50.59% in after-hours trading following the announcement that the first patient with recurrent glioblastoma was treated using its Alpha DaRT® technology in a pilot study. The milestone, conducted at The Ohio State University, marks a critical step in advancing the treatment for a highly aggressive brain cancer with limited therapeutic options. The company highlighted regulatory support, including the FDA’s Breakthrough Device Designation, and emphasized the treatment’s precision in targeting tumors while sparing healthy tissue. The trial aims to evaluate feasibility and safety, with enrollment of up to ten U.S. patients planned. The news reflects progress in Alpha Tau’s strategy to commercialize Alpha DaRT, addressing a significant unmet medical need and bolstering investor confidence in its potential market adoption.